Sartans May Improve Survival, Time to Recurrence in Liver Cancer

Share this content:
For patients with hepatocellular carcinoma, angiotensin II receptor 1 blockers (sartans) correlate with significantly improved survival.
For patients with hepatocellular carcinoma, angiotensin II receptor 1 blockers (sartans) correlate with significantly improved survival.

For patients with hepatocellular carcinoma after radiofrequency ablation, angiotensin II receptor 1 blockers (sartans) correlate with significantly improved overall survival and time to recurrence, according to a study published in the Journal of Gastroenterology and Hepatology.

Antonio Facciorusso, M.D., from the University of Foggia in Italy, and colleagues examined whether sartans delay time to recurrence and prolong overall survival using data from 153 patients with hepatocellular carcinoma after radiofrequency ablation.

The study population was classified into patients who received neither angiotensin converting enzyme inhibitors nor sartans (Group 1; 73 patients); patients treated with angiotensin converting enzymes (Group 2; 49 patients); and patients treated with sartans (Group 3; 31 patients).

Within the study population, 85.6 percent were in Child-Pugh A class and 89.6 percent were in Barcelona Clinic Liver Cancer A stage. The researchers found that the median overall survival was 48, 72, and 84 months in Groups 1, 2, and 3, respectively (P = 0.02).

RELATED: Immune Response to Chemo Improves PFS in Colorectal Cancer Liver Metastases

In the three groups, the median time to recurrence was 26, 44, and 69 months, respectively (P = 0.02). In multivariate analysis, sartan therapy significantly predicted longer overall survival and delayed time to recurrence.

"Sartans significantly improved overall survival and time to recurrence after radiofrequency ablation in hepatocellular carcinoma patients," the authors write.

Reference

  1. Facciorusso A, Del Prete V, Crucinio N, et al. Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients. Journal of Gastroenterology and Hepatology. [published online ahead of print October 12, 2015]. DOI: 10.1111/jgh.12988.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters